Clinical trial
The Effect of Ocrelizumab on the Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in Patients with Multiple Sclerosis Previously Treated with Disease Modifying Therapy - a Prospective Exploratory Observational Study
NCT04874597 is registered in ClinicalTrials.gov with Dr Recai Turkoglu as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effect of Ocrelizumab on the Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in Patients with Multiple Sclerosis Previously Treated with Disease Modifying Therapy - a Prospective Exploratory Observational Study
- Lead sponsor
- Dr Recai Turkoglu
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- November 15, 2021
- Completion date
- April 15, 2025
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.